CD274 and non-small cell lung carcinoma: Kichenadasse et al. (Kichenadasse et al., 2020) and Cortellini et al. (Cortellini et al., 2020) found that progression free survival (PFS)/overall survival (OS) in NSCLC patients with high body mass index (BMI) were longer than patients with low BMI during anti-PD-1/PD-L1 treatment.